Roche chops TNBC pro­grams fol­low­ing PhI­II flops, fur­ther dim­ming the spot­light on Ar­ray drug

One of Roche’s spot­light PhI­II can­cer drug hope­fuls is los­ing more of its au­ra.

All but pulling the plug on the ipatasert­ib pro­gram in triple-neg­a­tive breast can­cer, Roche dis­closed in a quar­ter­ly fil­ing that it’s killed two Phase III pro­grams: IPATu­ni­ty-130, which was test­ing the ATK block­er plus chemother­a­py in front­line TNBC or hor­mone re­cep­tor-pos­i­tive breast can­cer, and IPATu­ni­ty-170, which fo­cus­es on a com­bi­na­tion of ipatasert­ib, Tecen­triq and tax­ane in front­line TNBC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER